Methods of treating an inflammatory-related disease

Abstract

The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.

What is claimed is: 
     
         1 . A method of treating an animal having an inflammatory related disease selected from the group consisting of: diabetes type I; Sjorgen's syndrome; uveitis; allergic conjunctivitis; celiac disease; and non-specific colitis, the method comprising administering a compound selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
       to the animal in need thereof, wherein the compound is administered in an amount sufficient to treat diabetes type I; Sjorgen's syndrome; uveitis; allergic conjunctivitis; celiac disease; and non-specific colitis. 
     
     
         2 . The method according to  claim 1 , wherein the animal is a human being. 
     
     
         3 . The method according to  claim 2 , wherein the disease is celiac disease or non-specific colitis. 
     
     
         4 . The method according to  claim 2 , wherein the compound is administered at a concentration sufficient to inhibit a cytokine selected from the group consisting of: IL-1α, β, IL-2, IL-3, IL-6, IL-7, IL-9, IL-12, IL-17, IL-18, TNF-α, LT, LIF, Oncostatin, and IFNc1α, β, γ; but the amount is less than sufficient to substantially inhibit cyclin dependent kinases. 
     
     
         5 . The method according to  claim 2 , wherein the amount is between 5 mg and 80 mg per day. 
     
     
         6 . The method according to  claim 2 , wherein the amount is between 5 mg and 60 mg per day. 
     
     
         7 . The method according to  claim 2 , wherein the amount is between 5 mg and 45 mg per day. 
     
     
         8 . The method according to  claim 2 , wherein the amount is less than sufficient to inhibit 50% of cyclin dependent kinases (CDKs) selected from the group consisting of: CDK2, CDK4, and CDK6. 
     
     
         9 . The method according to  claim 8 , wherein the amount is less than sufficient to inhibit 40% of cyclin dependent kinases selected from the group consisting of: CDK2, CDK4, and CDK6. 
     
     
         10 . The method according to  claim 9 , wherein the amount is less than sufficient to inhibit 30% of cyclin dependent kinases selected from the group consisting of: CDK2, CDK4, and CDK6. 
     
     
         11 . The method according to  claim 8 , wherein the cyclin dependent kinase is CDK2. 
     
     
         12 . The method according to  claim 8 , wherein the cyclin dependent kinase is CDK4. 
     
     
         13 . The method according to  claim 9 , wherein the cyclin dependent kinase is CDK6. 
     
     
         14 . The method according to  claim 2 , further comprising an anti-inflammatory agent. 
     
     
         15 . The method according to  claim 14 , wherein the anti-inflammatory agent is selected from the group consisting of an analgesic; an antirheumatic agent; an gastrointestinal agent; a gout preparation; glucocorticoids; opthalmic preparation; respiratory agent; a nasal preparation; and a mucous membrane agent. 
     
     
         16 . The according to  claim 15 , wherein the analgesic is selected, from the group consisting of naproxen, indomethacin, ibuprofen, ketorolac tromethamine, choline magnesium trisalicylate and rofecoxib; the antirheumatic agent is selected from the group consisting of: cyclosporine, sulfasalazine, valdecoxib, penicillamine and dexamethasone; the gastrointestinal agent is selected from the group consisting of: mesalamine, balsalazide disodium and olsalazine sodium; the gout preparation is sulindac; the glucocorticoid is selected from the group consisting of dexamethasone, dexamethasone phosphate, methylprednisolone acetate, hydrocortisone and hydrocortisone sodium phosphate; the nasal preparation is selected from the group consisting of beclomethasone dipropionate monohydrate, fluticasone propionate, triamcinolone acetonide, flunisolide, mometasone furoate monohydrate and budesonide; the opthalmic preparation is ketorolac tromethamine; the respiratory agent is nedocromil sodium; and the mucous membrane agent is selected from the group consisting of alclometasone dipropionate, hydrocortisone butyrate, flurandrenolide, betamethasone valerate and clobetasol propionate. 
     
     
         17 . The method of  claim 2 , wherein meisoindigo is in an oral single dosage unit form comprising between 5 mg to 45 mg. 
     
     
         18 . The method according to  claim 5 , wherein the disease is celiac disease or non-specific colitis. 
     
     
         19 . The method according to  claim 5 , wherein the disease is uveitis. 
     
     
         20 . A method of treating an animal having: diabetes type I; Sjorgen's syndrome; uveitis; allergic conjunctivitis; celiac disease; and non-specific colitis, the method comprising administering to the animal 5 mg to 80 mg per day of a compound selected from the group consisting of: